Astrazeneca Pharma

AstraZeneca Pharma India obtained permission from the Central Drugs Standard Control Organisation to import and market Benralizumab, branded as Fasenra, for an additional indication — Hypereosinophilic Syndrome (HES) in patients aged 12 years and older without an identifiable non-haematologic secondary cause. The July 15, 2026 approval covers the 30 mg/ml solution for injection in a pre-filled syringe. The drug, which depletes eosinophils, is already used globally for severe eosinophilic asthma; the new indication targets a rare disorder characterised by elevated eosinophil counts. AstraZeneca stated that the permission enables the launch of Fasenra for HES in India, subject to related statutory approvals.

Powered by Tijori

July 16 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA - RECEIVES PERMISSION TO IMPORT BENRALIZUMAB (FASENRA) FOR ADDITIONAL INDICATION

Source text: ID:nBSE4Rs2Sz

Further company coverage: ASTR.NS

(([email protected];))

AstraZeneca Pharma India received permission from India's drug regulator to import and market its antibody-drug conjugate Trastuzumab deruxtecan, sold as Enhertu, for a new indication: first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults, in combination with pertuzumab. The approval from the Central Drugs Standard Control Organization expands the drug's eligible patient pool in India beyond any previously cleared indications. Enhertu is a globally established therapy that generated over $3 billion in sales worldwide in the last financial year. The company said the permission paves the way for marketing the drug for the specified indication, subject to any related statutory approvals.

Powered by Tijori

June 11 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA - RECEIVED PERMISSION TO IMPORT FOR SALE OF TRASTUZUMAB DERUXTECAN

Source text: ID:nBSE6vFWJS

Further company coverage: ASTR.NS

(([email protected];))

** Biopharma company Astrazeneca Pharma India's shares ASTR.NS fall as much as 6.76% to 8,357 rupees apiece

** This is stock's steepest intraday decline in two months

** ASTR posts a 23% year-on-year drop in March quarter profit; operating profit slips 29.5%

** Stock is most active in six weeks, with a trading volume of 35,516 shares as of 12:17 p.m. IST, more than quadruple the 30-day average volume, data compiled by LSEG shows

** ASTR shares are down 5.8% in 2026 so far, according to exchange data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

May 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA LTD MARCH-QUARTER PAT 448.8 MILLION RUPEES

• ASTRAZENECA PHARMA INDIA LTD MARCH-QUARTER REVENUE FROM OPERATIONS 5.79 BILLION RUPEES

Further company coverage: ASTR.NS

(([email protected];))

March 17 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT DURVALUMAB (IMFINZI) FOR ADDITIONAL INDICATION

Source text: ID:nBSE4YQpNZ

Further company coverage: ASTR.NS

(([email protected];;))

Feb 11 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA DEC-QUARTER PAT 325.9 MILLION RUPEES

• ASTRAZENECA PHARMA INDIA DEC-QUARTER REVENUE FROM OPERATIONS 6.12 BILLION RUPEES

Source text: ID:nBSE5MKvG0

Further company coverage: ASTR.NS

(([email protected];))

Feb 10 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA LTD - RECEIVES PERMISSION TO IMPORT DURVALUMAB

• ASTRAZENECA PHARMA - PERMISSION PAVES WAY FOR MARKETING OF DURVALUMAB SOLUTION IN INDIA

Source text: ID:nBSE4kw3HB

Further company coverage: ASTR.NS

(([email protected];))

Sept 12 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA - GETS SHOW CAUSE NOTICE FROM NATIONAL PHARMACEUTICAL PRICING AUTHORITY

• ASTRAZENECA PHARMA INDIA LTD - NPPA ALLEGES OVERCHARGING FOR 'SYMBICORT TURBUHALER'

• ASTRAZENECA PHARMA INDIA LTD - CLAIM QUANTUM 605 MILLION RUPEES

Source text: ID:nNSEb5xzyw

Further company coverage: ASTR.NS

(([email protected];))

Sept 2 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• SURRENDERS MANUFACTURING LICENSE

Source text: ID:nBSE3qVVyp

Further company coverage: ASTR.NS

(([email protected];))

Aug 14 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• JUNE-QUARTER PAT 558.3 MILLION RUPEES

• JUNE-QUARTER REVENUE FROM OPERATIONS 5.26 BILLION RUPEES

Source text: [ID:]

Further company coverage: ASTR.NS

(([email protected];;))

June 26 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA: EXPANDS BANGALORE GLOBAL HUB IN INDIA WITH 1.66 BILLION RUPEES INVESTMENT

Further company coverage: ASTR.NS

(([email protected];))

June 9 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• ASTRAZENECA PHARMA INDIA LTD - SANJEEV KUMAR PANCHAL HAS OFFERED TO RESIGN AS MD

Source text: [ID:]

Further company coverage: ASTR.NS

(([email protected];))

** AstraZeneca Pharma India ASTR.NS shares up 11.5% at 8,885 rupees, marking their biggest pct jump so far this year

** ASTR on Friday reported 48% surge in Q4 profit on strong performance of oncology and biopharma divisions

** AstraZeneca shares up 21.6% YTD vs 8.8% fall in Nifty pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected] ))

May 29 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT OSIMERTINIB TABLETS

Source text: ID:nNSE5r4vcG

Further company coverage: ASTR.NS

(([email protected];;))

May 8 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES APPROVAL FOR ENHERTU IN INDIA

Source text: ID:nNSEXz4FK

Further company coverage: ASTR.NS

(([email protected];;))

April 15 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• SURRENDERS MARKETING AUTHORISATION FOR OLAPARIB TABLETS

• DISCONTINUATION DUE TO COMMERCIAL REASONS, NOT EFFICACY OR SAFETY

• HOLDS ALL OTHER PERMISSIONS FOR OLAPARIB IN INDIA

• NEVER MARKETED OLAPARIB INDICATION IN INDIA

Source text: ID:nBSE1YlFfg

Further company coverage: ASTR.NS

(([email protected];;))

March 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• DISCONTINUING MANUFACTURING, MARKETING OF PROLONGED RELEASE ISOSORBIDE-5-MONONITRATE TABLETS BP

Source text: [ID:]

Further company coverage: ASTR.NS

(([email protected];))

** AstraZeneca Pharma India ASTR.NS rises 2.1% to 7,622.9 rupees, highest in about a month

** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution

** Drug is used to treat patients with a certain type of lung cancer

** Shares trading above 50-, 100-, 200-day moving avg

** ASTR up 2.2% YTD, after gaining 32% in 2024

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

March 7 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT DURVALUMAB SOLUTION

• PERMISSION PAVES WAY FOR MARKETING DURVALUMAB SOLUTION IN INDIA

Source text: ID:nNSEb26vVv

Further company coverage: ASTR.NS

(([email protected];;))

March 6 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT PHARMACEUTICAL FORMULATIONS OF LOKELMA

Source text: ID:nNSE5FXNVQ

Further company coverage: ASTR.NS

(([email protected];;))

** AstraZeneca Pharma ASTR.NS rises 2.7% to 6,872.1 rupees; stock's biggest one-day gain since Feb. 3

** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution

** Drug is used to treat patients with a certain type of liver cancer

** Shares mark second-busiest session in about 2 weeks, with more than 11,000 shares traded

** Stock down 8% so far this year, after a 32% gain from 2024

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Feb 28 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS:

• RECEIVES PERMISSION TO IMPORT DURVALUMAB FOR ADDITIONAL INDICATION

• GETS PERMISSION FROM CENTRAL DRUGS STANDARD CONTROL ORGANISATION, INDIA

Source text: ID:nNSE3QqT8W

Further company coverage: ASTR.NS

(([email protected];;))

** Astrazeneca Pharma India ASTR.NS rises 2% to 7,609 rupees

** Q3 profit before exceptional item and tax jumps ~3.7x y/y, helped by strong demand for its oncology products; rev up 44%

** Co incurred one-off 335.5 million rupees ($3.9 mln) employee separation cost in the quarter

** More than 41,000 shares traded, 1.5x the 30-day avg

** Stock rose 32% in 2024

($1 = 86.8200 Indian rupees)

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

BENGALURU, Feb 11 (Reuters) - Diary of India economic, corporate events on Feb 11

ECONOMIC, CORPORATE .BSE500 EVENTS:

NTS - 'No time scheduled'

(Compiled by Bengaluru Newsroom)

(([email protected]))

Updates shares in paragraphs 1 and 3, add details on Wang in 11, and US headwinds in 15

By Pushkala Aripaka and Maggie Fick

Feb 6 (Reuters) - AstraZeneca AZN.L on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising investor hopes that the impact of several probes in the country could be minor and leading its shares to rise about 5%.

The stock was hit hard last year by news of a string of investigations into the company's executives and activities in China, which is the crown jewel of the company's international business, accounting for 12% of total sales in 2024.

The shares were among the top gainers on Britain's blue-chip FTSE-100 .FTSE index at 1105 GMT after AstraZeneca also forecast 2025 sales above expectations and raised its dividend for the current year.

Redburn Atlantic analyst Simon Baker said the update on the import investigation was "very reassuring" and confirmed that likely financial penalties "would be a fraction of the extreme scenarios discounted in the stock last year".

The company said that, to the best of its knowledge, the import taxes related to cancer drugs Imfinzi and Imjudo, adding that it continued to cooperate with authorities.

A fine of between one and five times the unpaid tax of $900,000 could be levied if the company is found liable, AstraZeneca said.

That investigation could possibly extend to include another of the company's best-selling cancer drugs, Enhertu, CEO Pascal Soriot said at a press conference after the release of results.

'SOOTHING'

Thursday's share price rise shows investor focus returning to the strength of the company's drug pipeline, said AstraZeneca shareholder Lucy Coutts at investment firm JM Finn.

"The short statement was soothing with a small decline in (China) sales primarily as a result of low respiratory infections rather than investigation headwinds."

Last December, AstraZeneca named Iskra Reic as its new international executive vice president, who took over from Leon Wang in efforts to stabilise operations in China after Wang was detained by Chinese authorities in October.

On Thursday, Soriot said the company had no further information to provide about Wang and was not permitted by Chinese authorities to speak to him, adding that AstraZeneca had shared information with authorities when it was approached.

Shares plunged after the news of Wang's detention, wiping about $18 billion off the company's value. They have since recovered and are up more than 10% this year, including Thursday's gains.

AstraZeneca forecast 2025 revenue to increase by a high single-digit percentage, with core earnings projected to grow by a low double-digit percentage, at constant currency rates, after it also beat fourth-quarter sales and profit expectations.

Analysts expect 2025 sales growth of 6.5% and profit to rise by 12.6%, according to a LSEG poll.

Still, AstraZeneca cautioned about some headwinds, including in the United States, over changes in Medicare drug price negotiations.

(Reporting by Pushkala Aripaka in Bengaluru and Maggie Fick in London. Editing by David Goodman and Mark Potter)

(([email protected]; X and LinkedIn: @pullthekart;))

By Maggie Fick

LONDON, Feb 5 (Reuters) - AstraZeneca AZN.L investors will look past another strong set of quarterly results on Thursday to focus on the main issue overhanging shares: an investigation of a top executive by authorities in China, one of its key markets.

The group said on Oct. 31 that its China head Leon Wang, who also led its international business as an executive vice president, had been detained by the Chinese authorities. It said it did not know what the investigation was about.

Unless the company discloses fresh information about the probe and arrest at the release of fourth-quarter results, investors are likely to resume selling the stock even though the company's drug pipeline is viewed as strong, four healthcare investors and four analysts told Reuters.

"This blindsided the company," said AstraZeneca shareholder Lucy Coutts at investment firm JM Finn, noting the "void" of information about the probe.

"We don't have visibility on how or when this will be resolved," said Redburn Atlantic analyst Simon Baker. "This is the focus at the moment. It shouldn't be, but it is."

Wang's arrest was followed by other revelations, including that more than 100 former sales staff in China had been sentenced to jail time in a large and ongoing medical insurance fraud case.

In November the company reported a third investigation in China involving two current and two former senior executives, relating to the import of AstraZeneca cancer drugs from Hong Kong. It said the probe targeted only the individuals, not the company.

AstraZeneca declined to comment for this article ahead of results.

China has long been a key market for the drugmaker, the crown jewel of its international business that accounted for 13% of total sales in 2023.

The Anglo-Swedish group announced plans in 2023 to build a $450 million factory in China. It signed several licensing deals with Chinese companies that year, and bought a China-headquartered biotech company.

Chief Financial Officer Aradhana Sarin told investors at the JPMorgan Healthcare Conference last month the company anticipates some revenue impact on its China business in the fourth quarter and into 2025. Investors are hoping for more information on Thursday.

SMALL RECOVERY

AstraZeneca shares have recovered after the initial news of Wang's detention wiped around $18 billion off their value. They are up about 2% since early November.

In December, AstraZeneca replaced Wang with senior executive Iskra Reic as executive vice president for international, based in Shanghai.

Several investors said it may be tough for an executive who does not speak Mandarin and has never lived in China to navigate such a complicated market at a very sensitive time.

Barclays analysts said in a recent note they believe AstraZeneca may pay a penalty to resolve the Wang investigation. In 2014, British drugmaker GSK GSK.L was fined nearly 300 million pounds ($372 million) by a Chinese court for bribery.

"Whilst there could be some commercial impact coming from lack of promotion whilst the investigation is ongoing, we view this as digestible given the momentum elsewhere in the business," Barclays said.

($1 = 0.8054 pounds)

(Reporting by Maggie Fick; Editing by Josephine Mason and Jan Harvey)

(([email protected]; +44 7890 916706;))

Adds new items, updates futures

Feb 4 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Tuesday, with futures FFIc1 down 0.18%.

* DIAGEO: Diageo DGE.L withdrew its medium-term organic sales growth target, citing macroeconomic and geopolitical uncertainty.

* VODAFONE: Vodafone VOD.L reported another deterioration in Germany in its third quarter, a weak point amid otherwise stronger trading in Britain, Turkey and Africa.

* CREST NICHOLSON: Housebuilder Crest Nicholson CRST.L posted a 53% drop in 2024 fiscal year earnings, in line with market view.

* TULLOW OIL: Tullow Oil TLW.L said it has appointed its finance chief Richard Miller as interim chief executive officer, effective Feb. 14.

* RIO TINTO: Rio Tinto RIO.AX, RIO.L said on Tuesday it had begun clearing iron ore ships from two Western Australian ports as two tropical cyclones offshore swell seas and complicate efforts to repair infrastructure damaged by a previous cyclone last month.

* AstraZeneca: Britain on Monday hit back at AstraZeneca AZN.L over the collapse of a 450 million pound ($558.5 million) investment, saying it had scaled back the research and development portion of its plans, resulting in a lower offer of government support.

* GENERAL PHARMACEUTICAL COUNCIL: Britain's pharmacies regulator tightened rules for online pharmacies' prescribing obesity drugs, ordering them to make changes to prevent people from receiving drugs that could cause them harm.

* OIL: U.S. crude prices fell by nearly 2% as U.S. tariffs on China took effect

* METALS: LME copper prices edged higher after a sharp pullback in the previous session

* GOLD: Gold prices firmed as U.S. tariff and inflation concerns boosted safe-haven demand.

* For more on the factors affecting European stocks, please click on: LIVE/

TODAY'S UK PAPERS
> Financial Times PRESS/FT
> Other business headlines PRESS/GB

(Reporting by Raechel Thankam Job)

(([email protected]))

Adds government response in paragraphs 9-10, other investment in paragraph 8

LONDON, Jan 31 (Reuters) - AstraZeneca AZN.L on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England, citing a cut in British government support.

The decision to ditch the development of an existing facility in the Speke area of Liverpool comes at a time when Prime Minister Keir Starmer is pushing hard to drum up investment in Britain to generate economic growth.

"Following discussions with the current government, we are no longer pursuing our planned investment at Speke," a spokesperson for the London-listed bluechip drugmaker said in a statement.

"Several factors have influenced this decision, including the timing and reduction of the final offer compared to the previous government's proposal."

Earlier this week finance minister Rachel Reeves named AstraZeneca as one of the "great companies" she said were delivering jobs and investment across the country.

Her speech, focused on how to get the country's stagnant economy growing again, set out the importance of attracting investment and said the government was "determined to make Britain the best place in the world to invest".

The spokesperson for AstraZeneca, which also plans to spend 200 million pounds to expand its existing Cambridge presence, said the Liverpool site would continue to produce flu vaccines.

Over the past year, the company has set out billions of dollars worth of investment in various countries, from Singapore and Thailand to France and Canada.

The most notable among those was the Anglo-Swedish drugmaker's $2 billion spending proposal on research and development and manufacturing plants in the United States.

Britain's finance ministry said a change in "the make-up" of the investment originally proposed by AstraZeneca had led to a reduced government grant offer being made.

"All government grant funding has to demonstrate value for the taxpayer and unfortunately, despite extensive work from government officials, it has not been possible to achieve a solution," a government spokesperson said.

The Financial Times reported in August 2024 that AstraZeneca had warned it could relocate its vaccine manufacturing site from Britain to the United States as talks with the Labour government over state aid had become deadlocked.

The newspaper said Reeves wanted to reduce state provisions to the company's vaccine centre, which would cut the pledge made by the previous administration from about 90 million pounds to 40 million pounds.

The previous government's offer included up to 70 million in grants to develop the facility in Speke, the FT report said.

($1 = 0.8060 pounds)

(Reporting by Maggie Fick in London, Yamini Kalia in Bengaluru, additional reporting by Muvija M, writing by William James; Editing by Kate Holton and Jan Harvey)

(([email protected];))